

Figure S1. Plinabulin triggers cytoprotective autophagy in glioblastoma. a, The glioblastoma cells were exposed to DMSO or various concentrations (4, 8, 16 nM) of plinabulin for 24 h, and the expression levels of LC3 were analyzed through western blot. b, Glioblastoma cells underwent a pretreatment phase with Baf-A1 lasting 1 h, followed by treatment with DMSO or plinabulin at the indicated concentrations for 72 h, and the assessment of synergy scoring was conducted using the online SynergyFinder software. c, Glioblastoma cells underwent a pretreatment phase with CQ lasting 1 h, followed by treatment with DMSO or plinabulin at the indicated concentrations for 72 h, and the evaluation of synergy scoring was conducted using the online SynergyFinder software. d, A172 cells were incubated with 24 nM plinabulin and/or 24  $\mu$ M CQ, while the control group was treated with DMSO. T98G cells were incubated with 12 nM plinabulin and/or 36  $\mu$ M CQ, while the control group was treated with DMSO. The expression of cleaved-PARP and Mcl-1 was analyzed by western blot after treating for 48 h. e, Glioblastoma cells were exposed with 12 nM plinabulin and/or 3 mM 3-MA, while the control group was treated with DMSO. The expression of p-mTOR and EGFR was analyzed by western blot after treating for 24 h and cleaved-PARP was analyzed by western blot after treating for 48 h.